Other Targets

​Vast is also interested in partnering to further evaluate the efficacy of its proprietary nitric oxide-release compounds against other respiratory diseases, including tuberculosis (TB), aspergillosis, hospital-acquired bacterial pneumonia (HABP), and ventilator acquired bacterial pneumonia (VABP).

Bronchiectasis >